Australia's largest stock trading and investment forum Australia's #1 stock forum

MSB

3.21%

$1.13 mesoblast limited

banter and General Discussion, page-10537

First 10537 Last

Share
Profile

Follow
Wilba32

6,921 Posts.

1521

17/08/24

08:30

Post #: 75248690
Share

Originally posted by Phaedrus: ↑

Hi Reg,

I think Matt Klinker’s face has put on a lot more weight since his LinkedIn photo was last updated - I say that having reluctantly viewed ‘Matt the Mouth’ & his unviral wannabe-influencer video, currently running on the FDA site.

And that’s a good thing, IMO.

Someone thinks Matt can be the, or at least a, poster-child for FDA’s policy-sharing informing & industry updating role on HCT/P at CBER - possibly his besty, Marks, or Verdun.

But why do that? These standing information videos on FDA’s official public site are as rare as unicorns.

I have a couple of ideas. The one I like most is that CBER wants Matt to be a lightning-rod for administrative acclaim or censure on the potency issue, especially for HCT/Ps. IMO he came into cellular therapies at FDA with an arrogant belief in the primacy of his own research, worked with Bauer in his horribly conflicted FDA research labs.

And then - by setting bars in the clouds & taking away the ladders - contributed to CBER holding back on anything to do with ‘stem cell’ therapies for ages.

This cost America in many ways, all of which the FDA can try to ignore. But as bureaucrats they can’t ignore increasing BLAs in their inbox and they can’t ignore the industry funding under PDUFA, & their statutory obligation to provide guidance on how to satisfy CRLs.

So, Matt gets a promotion after the ODAC debacle, but the condition is that he has to put his name to the new full message I.e. that FDA can be flexible. On potency. And there he is in the video saying things that he never said at ODAC in the PM session which he so rudely interrupted.

And his face is a bit heavier. Welcome to the real-world Matt.

Expand

I’m going to have to watch the video now!

MSB Price at posting: $1.01 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

There are more pages in this discussion • 530 more messages in this thread...

First 10537 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
2	27197	1.105
8	87146	1.100
2	71941	1.095
2	33264	1.090
2	18897	1.085

Price($)	Vol.	No.
1.125	43578	3
1.130	87126	8
1.135	1090	1
1.140	141598	9
1.145	64500	3

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

banter and General Discussion, page-10537

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

banter and General Discussion, page-10537

Top Stories

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News